S
KROS icon

SignatureFD’s Keros Therapeutics KROS Stock Holding History

SignatureFD’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,280
Closed -$14.1K – 3574
2026
Q1 		$14.1K Sell
1,280
-682
-35% -$10.5K ﹤0.01% 2362
2025
Q4 		$39.9K Buy
1,962
+311
+19% +$5.46K ﹤0.01% 1779
2025
Q3 		$26.1K Buy
1,651
+354
+27% +$5.23K ﹤0.01% 1981
2025
Q2 		$17.3K Buy
1,297
+300
+30% +$4.05K ﹤0.01% 2110
2025
Q1 		$10.2K Buy
997
+921
+1,212% +$10.7K ﹤0.01% 2350
2024
Q4 		$1.2K Hold
76
– – ﹤0.01% 2990
2024
Q3 		$4.41K Hold
76
– – ﹤0.01% 2611
2024
Q2 		$3.47K Hold
76
– – ﹤0.01% 2617
2024
Q1 		$5.03K Hold
76
– – ﹤0.01% 2537
2023
Q4 		$3.02K Buy
+76
New +$2.38K ﹤0.01% 2657
2023
Q2 		– Sell
-10
Closed -$427 – 3304
2023
Q1 		$427 Hold
10
– – ﹤0.01% 3118
2022
Q4 		$480 Hold
10
– – ﹤0.01% 3115
2022
Q3 		$0 Buy
+10
New +$347 ﹤0.01% 3231
2022
Q2 		– Sell
-13
Closed -$1K – 3238
2022
Q1 		$1K Buy
+13
New +$667 ﹤0.01% 3016
2021
Q3 		– Sell
-18
Closed -$1K – 3134
2021
Q2 		$1K Buy
+18
New +$975 ﹤0.01% 2754

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SignatureFD's KROS Position: Q2 2026 in Review

SignatureFD sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 1,280 shares — an estimated $14.1K sold.

SignatureFD first reported a position in KROS in Q2 2021 and held it in 15 quarters. The position peaked at $39.9K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • SignatureFD reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SignatureFD sold 1,280 Keros Therapeutics shares in Q2 2026, an estimated $14.1K.
  • SignatureFD first reported a position in Keros Therapeutics in Q2 2021 and held it in 15 quarters.
  • SignatureFD's Keros Therapeutics position peaked at $39.9K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.